Financial Results
Minapharm Pharmaceuticals (MIPH.CA) Reports Its Financial Results (Standalone) for The Period ending 31/12/2025
AI Summary
AI-powered disclosure summary — Coming soon 🔜
Company Name: Minapharm Pharmaceuticals
ISIN Code: EGS380G1C011
Currency: Egyptian Pound
F/S (Standalone) Period: From 01/01/2025 to 31/12/2025
Net profit: 57,472,127
F/S (Standalone) Period: From 01/01/2024 to 31/12/2024
Net Comparative profit: 162,791,407
Audit Status: Audited
Source: Minapharm Pharmaceuticals
Financial statements ending on 31-12-2025
The BoD Report in Arabic (3,896 KB)
The Corporate Governance Report in Arabic (8,234 KB)
The ESG Report in English (7,204 KB)
The TCFD Report in English (3,723 KB)
The TCFD Report in Arabic (2,320 KB)
The BoD Report in English (3,876 KB)
The Corporate Governance Report in English (10,562 KB)
The ESG Report in Arabic (4,399 KB)
ISIN Code: EGS380G1C011
Currency: Egyptian Pound
F/S (Standalone) Period: From 01/01/2025 to 31/12/2025
Net profit: 57,472,127
F/S (Standalone) Period: From 01/01/2024 to 31/12/2024
Net Comparative profit: 162,791,407
Audit Status: Audited
Source: Minapharm Pharmaceuticals
Financial statements ending on 31-12-2025
The BoD Report in Arabic (3,896 KB)
The Corporate Governance Report in Arabic (8,234 KB)
The ESG Report in English (7,204 KB)
The TCFD Report in English (3,723 KB)
The TCFD Report in Arabic (2,320 KB)
The BoD Report in English (3,876 KB)
The Corporate Governance Report in English (10,562 KB)
The ESG Report in Arabic (4,399 KB)